{"slideshow_credits": null, "snippet": "The deal to acquire Cadence Pharmaceuticals is expected to expand Mallinckrodt\u2019s specialty pharmaceutical offerings and its product reach in hospitals.", "abstract": "The deal to acquire Cadence Pharmaceuticals is expected to expand Mallinckrodt\u2019s specialty pharmaceutical offerings and its product reach in hospitals.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 1, "organization": ""}], "original": "By CHAD BRAY"}, "web_url": "http://dealbook.nytimes.com/2014/02/11/mallinckrodt-to-buy-san-diego-biopharmaceutical-firm-for-1-3-billion/", "lead_paragraph": null, "headline": {"main": "Mallinckrodt to Buy San Diego Biopharmaceutical Firm for $1.3 Billion", "print_headline": "Hospital Deal", "kicker": "DealBook"}, "_id": "52fa21c238f0d810dc0917a0", "word_count": "197", "multimedia": [], "pub_date": "2014-02-11T08:11:42Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Mallinckrodt Pharmaceuticals", "rank": "2"}, {"name": "organizations", "value": "Cadence Pharmaceuticals Inc", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}